scalp psoriasis

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52[...]

By afschroeder • May 10, 2026

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis

Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee[...]

By sjmartinez • December 21, 2023